Investor Presentaiton
Syapse-Company Overview
Market Segment:
Headquarters:
CEO:
COMPANY OVERVIEW
Precision Medicine
San Francisco, CA
Ken Tarkoff
• Multi-sided platform creating a data network effect in order to improve
the way cancer and other diseases are treated
Origin:
Capital:
Ownership:
syapse
SUMMARY
June 2014
$25.0M
11% Primary/9% Fully Diluted
Series B, Series C, Series D, Series E, Series F, Series
G (February 2021)
Amgen Ventures, Ascension Ventures,
•
Health systems contribute clinical and other data to the platform and
receive clinical and business insights
•
Pharma, on the other side of the platform, purchases insights and
delivers information back to health systems
Financing Rounds:
Syapse collects and networks data from siloed hospital and laboratory
enterprise systems (Syapse Network) allows the Company to provide
solutions for pharma including real world evidence generation,
identification of patients for clinical trials and hub services
Other Investors:
•
Ecosystem partnerships with Pfizer, Amgen, others TBA
Board Member:
Gary Kurtzman
Intermountain Healthcare Innovation Fund, Merck
GHIF, Medidata Ventures, Northpond Ventures,
Revelation Partners, Social Capital
THESIS
REVENUE MODEL
•
Syapse is initially focused on oncology, opportunity to leverage the
platform to other disease verticals anticipated in 2020 and beyond
Scalability allows targeting of large community health systems (50% of
oncology pts in U.S) and ex-U.S, expansion
$9B U.S./$15B Global market opp. from pharma partnerships and $250M
U.S./$1B Global market opp. from health systems in oncology
Syapse contracts with pharma and other ecosystem relationships via
multi-year license agreements for products across RWE, clinical trial,
regulatory, and commercial use cases.
COMPETITORS
Flatiron Health, Cota, Tempus Health, Concerto
G
www.safeguard.com
© 2021 Safeguard Scientifics, Inc. All rights reserved.
SFE
LISTED
NYSE
23View entire presentation